<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01506505</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2011-001120-38</org_study_id>
    <nct_id>NCT01506505</nct_id>
  </id_info>
  <brief_title>The Evening Versus Morning Polypill Utilization Study</brief_title>
  <acronym>TEMPUS</acronym>
  <official_title>A Randomised Controlled Cross-over Trial to Evaluate Evening Versus Morning Administration of a Cardiovascular Polypill</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and rationale:&#xD;
&#xD;
      In clinical practice, antihypertensives are generally prescribed for use in the morning,&#xD;
      whereas some statins are recommended for use in the evening. There is evidence that the&#xD;
      reduction in LDL cholesterol achieved with some statins is superior when taken in the night,&#xD;
      but it is unclear whether the additional reduction in LDL cholesterol(and the reported&#xD;
      improvement in BP control when aspirin is taken in the evening) is offset by a reduction in&#xD;
      adherence when taking medication in the evening. Current product labelling recommends night&#xD;
      use for simvastatin and does not state a timing preference for aspirin or blood pressure&#xD;
      lowering medicines. There is therefore uncertainty concerning the best timing of&#xD;
      administration of the polypill. This uncertainty will be addressed by this trial.&#xD;
&#xD;
      Trial design:&#xD;
&#xD;
      Randomised, open label cross over trial (n=75) of the polypill in the morning compared with&#xD;
      the evening administration compared with individual agent administration (acetylsalicylic&#xD;
      acid and blood pressure lowering agents in the morning, and statin in the evening) in&#xD;
      individuals at high risk of cardiovascular disease. Patients will be recruited to the RHP 2c&#xD;
      (acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg),&#xD;
      and will be randomly allocated to the sequence of time of administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and rationale:&#xD;
&#xD;
      In clinical practice, antihypertensives are generally prescribed for use in the morning,&#xD;
      whereas some statins are recommended for use in the evening. There is evidence that the&#xD;
      reduction in LDL cholesterol achieved with some statins is superior when taken in the night,&#xD;
      but it is unclear whether the additional reduction in LDL cholesterol(and the reported&#xD;
      improvement in BP control when aspirin is taken in the evening) is offset by a reduction in&#xD;
      adherence when taking medication in the evening. Current product labelling recommends night&#xD;
      use for simvastatin and does not state a timing preference for aspirin or blood pressure&#xD;
      lowering medicines. There is therefore uncertainty concerning the best timing of&#xD;
      administration of the polypill. This uncertainty will be addressed by this trial.&#xD;
&#xD;
      Trial design:&#xD;
&#xD;
      Randomised, open label cross over trial (n=75) of the polypill in the morning compared with&#xD;
      the evening administration compared with individual agent administration (acetylsalicylic&#xD;
      acid and blood pressure lowering agents in the morning, and statin in the evening) in&#xD;
      individuals at high risk of cardiovascular disease. Patients will be recruited to the RHP 2c&#xD;
      (acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg),&#xD;
      and will be randomly allocated to the sequence of time of administration.&#xD;
&#xD;
      Aim:&#xD;
&#xD;
      To measure whether there is a difference in LDL cholesterol levels or the 24 hour ambulatory&#xD;
      blood pressure in individuals at high risk of cardiovascular disease when the polypill is&#xD;
      taken in the morning compared to the evening.&#xD;
&#xD;
      Randomisation and trial treatment:&#xD;
&#xD;
      Eligible individuals willing to participate in the trial will receive the polypill for a&#xD;
      total of 18 weeks and be randomised to the sequence of 6 weeks morning, 6 weeks evening&#xD;
      administration and 6 weeks administration of the individual agents. The polypill will be&#xD;
      provided by the investigator at the Trial Centre. Participants will also receive information&#xD;
      about smoking cessation (if applicable) and how to follow a healthy heart diet. They will be&#xD;
      advised to increase physical activity and lose weight if needed.&#xD;
&#xD;
      Data collection and follow-up:&#xD;
&#xD;
      Participants will be followed-up for 20 weeks. Ambulatory blood pressure will be measured at&#xD;
      baseline and week 6, week 12 and week 18. Fasting lipids will be measured at baseline, weeks&#xD;
      6, 12 and 18. Tolerability will be assessed at weeks 6, 12, 18 and 20 as will adverse events.&#xD;
      Participant acceptability will be measured at the end of the treatment period.&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      Difference in LDL cholesterol and mean 24 hour ambulatory systolic BP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL cholesterol (polypill evening vs polypill morning)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Differences between polypill in the evening (after 8 weeks of evening treatment) and polypill in the morning (after 8 weeks of morning treatment) in:&#xD;
- Mean LDL cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean 24 hour ambulatory systolic BP (polypill evening vs morning)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Difference between the between polypill in the evening (after 8 weeks of evening treatment) and polypill in the morning (after 8 weeks of morning treatment) in:&#xD;
- Mean 24 hour ambulatory systolic BP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in ambulatory BP parameters after a mean of 7 week of treatment (polypill evening vs. morning, polypill vs regular care)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Differences between polypill in the evening (after 8 weeks of evening treatment) and polypill in the morning (after 8 weeks of morning treatment) and regular care (after 8 weeks of treatment with individual agents of the polypill) in:&#xD;
Mean 24 hour ambulatory diastolic BP&#xD;
Mean diurnal (awake) and nocturnal (asleep) systolic and diastolic BP.&#xD;
Percentage of dipping of SBP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in tolerability (adverse event, cessation of treatment)</measure>
    <time_frame>Every 6-8 weeks</time_frame>
    <description>Difference between polypill in the evening (after 8 weeks of evening treatment) and polypill in the morning (after 8 weeks of morning treatment) and regular care (after 8 weeks of treatment with individual agents of the polypill) in:&#xD;
Patients' acceptability&#xD;
Number of adverse events&#xD;
Number of cessation of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence (polypill evening vs. morning, polypill vs regular care)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Differences between polypill in the evening (after 8 of evening treatment) and polypill in the morning (after 8 weeks of morning treatment) and regular care (after 8 weeks of treatment with individual agents of the polypill) in:&#xD;
Patients' adherence measured with electronic medication registration lids (MEM spots, AARDEX group)&#xD;
Patients' self reported adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol fractions (polypill evening vs. morning, polypill vs regular care)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Differences between polypill in the evening (after 8 of evening treatment) and polypill in the morning (after 8 weeks of morning treatment) and regular care (after 8 weeks of treatment with individual agents of the polypill) in:&#xD;
Mean total cholesterol.&#xD;
Mean HDL cholesterol.&#xD;
Mean triglycerides.&#xD;
Mean total:HDL ratio</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Cerebrovascular Disease</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Polypill in the morning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cardiovascular agents in a polypill used from 05.00-11.00 in the morning (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polypill in the evening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cardiovascular agents in a polypill used from 18.00-00.00 in the evening (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Individual agents of the polypill)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cardiovascular agents in as acetylsalicylic acid 75 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg used 05.00-11.00 in the morning.&#xD;
Simvastatin 40 mg used 18.00-00.00 in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cardiovascular Agents</intervention_name>
    <description>Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill</description>
    <arm_group_label>Individual agents of the polypill)</arm_group_label>
    <arm_group_label>Polypill in the evening</arm_group_label>
    <arm_group_label>Polypill in the morning</arm_group_label>
    <other_name>Acetylsalicylic acid 80 mg</other_name>
    <other_name>Simvastatin 40 mg</other_name>
    <other_name>Lisinopril 10 mg</other_name>
    <other_name>Hydrochlorothiazide 12,5 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant is able to give informed consent.&#xD;
&#xD;
          -  The trial Investigator considers that each of the polypill components are indicated at&#xD;
             the doses in the Red Heart Pill&#xD;
&#xD;
          -  Established atherothrombotic cardiovascular disease (CVD) or intermediate to high&#xD;
             cardiovascular risk, defined as;&#xD;
&#xD;
               -  History of coronary heart disease (myocardial infarction, stable or unstable&#xD;
                  angina pectoris, or coronary revascularisation procedure), or&#xD;
&#xD;
               -  History of ischaemic cerebrovascular disease (ischaemic stroke or transient&#xD;
                  ischaemic attack), or&#xD;
&#xD;
               -  History of peripheral vascular disease (peripheral revascularisation procedure or&#xD;
                  amputation due to vascular disease or aortic reconstruction), or&#xD;
&#xD;
               -  For individuals without established cardiovascular disease, a calculated 5 year&#xD;
                  CVD risk of 5% or greater (calculated using the 1991 Anderson Framingham risk&#xD;
                  equation with adjustments as defined by the New Zealand Guidelines Group&#xD;
                  recommendations - (Appendix 1))&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to any of the components of the polypill (e.g. known intolerance to&#xD;
             aspirin, statins, or ACE inhibitors; pregnancy or likely to become pregnant or&#xD;
             breastfeeding women during the treatment period). Such contraindications are fully&#xD;
             listed in the Investigator Brochures.&#xD;
&#xD;
          -  The treating doctor considers that changing a participant's cardiovascular medications&#xD;
             would put the participant at risk (e.g. symptomatic heart failure, high dose Î²-blocker&#xD;
             required to manage angina or for rate control in atrial fibrillation, accelerated&#xD;
             hypertension, severe renal insufficiency, a history of severe resistant hypertension).&#xD;
&#xD;
          -  Other potential reasons for exclusion include:&#xD;
&#xD;
          -  Known situation where medication regimen might be altered for a significant length of&#xD;
             time, e.g. current acute cardiovascular event, planned coronary bypass graft&#xD;
             operation.&#xD;
&#xD;
          -  Unlikely to complete the trial (e.g. life-threatening condition other than&#xD;
             cardiovascular disease) or adhere to the trial procedures or attend study visits (e.g.&#xD;
             major psychiatric condition, dementia).&#xD;
&#xD;
          -  Any reason, medical condition, ongoing medication or significant disability that would&#xD;
             prevent the participant complying with trial consent, treatment and follow-up&#xD;
             procedures or potentially jeopardise her / his medical care.&#xD;
&#xD;
          -  Night shift workers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Spiering, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2012</study_first_posted>
  <last_update_submitted>August 12, 2013</last_update_submitted>
  <last_update_submitted_qc>August 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>dr.Frank L.J. Visseren</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular prevention</keyword>
  <keyword>Polypill</keyword>
  <keyword>Combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

